CN Patent

CN118574622B — Senaparib和替莫唑胺的复方制剂及其制备方法

Assigned to Impact Therapeutics Inc · Expires 2026-04-03 · 0y expired

What this patent protects

本发明提供senaparib和替莫唑胺的复方制剂及其制备方法。本发明的复方制剂含有活性成分和药学上可接受的辅料，所述活性成分为senaparib和替莫唑胺，其中，以复方制剂总重计，senaparib的含量为2.0％～15.0％，替莫唑胺的含量为1.0％～10.0％。采用本发明所述的方法制备得到的复方制剂，两种药物都具有良好的溶出度，含量均匀度和稳定性。

USPTO Abstract

本发明提供senaparib和替莫唑胺的复方制剂及其制备方法。本发明的复方制剂含有活性成分和药学上可接受的辅料，所述活性成分为senaparib和替莫唑胺，其中，以复方制剂总重计，senaparib的含量为2.0％～15.0％，替莫唑胺的含量为1.0％～10.0％。采用本发明所述的方法制备得到的复方制剂，两种药物都具有良好的溶出度，含量均匀度和稳定性。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN118574622B
Jurisdiction: CN
Classification: —
Expires: 2026-04-03
Drug substance claim: No
Drug product claim: No
Assignee: Impact Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.